Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)

NACompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

May 10, 2022

Study Completion Date

June 15, 2022

Conditions
Cardiac SurgeryTransfusionPerioperative Anemia
Interventions
DRUG

EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)

"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value"

Trial Locations (1)

34295

DEpartement d'anesthésie et réanimation D - Arnaud de Villeneuve, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT04141631 - Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2) | Biotech Hunter | Biotech Hunter